{"doi":"10.1159/000238613","title":"UFT Is More Antineoplastic against Gastric Carcinoma than 5-Fluorouracil, 1-(2-Tetrahydrofuryl)-5-fluorouracil and 1-Hexylcarbamoyl-5-Fluorouracil","abstract":"<jats:p>The sensitivity of human gastric cancer tissue to 5-fluorouracil (5-FU) and its analogues l-(2-tetrahydrofuryl)-5-fluorouracil (FT), UFT and 1-hexylcarbamoyl-5-fluorouracil (HCFU) was determined, using the in vivo subrenal capsule (SRC) assay. The relative variation of tumor size (ΔTS/TS₀) was calculated as follows: ΔTS/TS₀ = (TS&lt;sub&gt;6&lt;/sub&gt;-TS₀/TS₀) x 100%, where TS&lt;sub&gt;6&lt;/sub&gt; was the tumor size on day 6 and TS₀ on day 0. The chemosensitivity was considered to be positive when ΔTS/TS₀ in the treated group decreased to below -10%. For their cytotoxic effects, 5-FU analogues are converted to 5-FU and positive correlations were noted between the tumor sizes of 5-FU and its analogues (5-FU vs. FT, r = 0.737; 5-FU vs. UFT, r = 0.653; 5-FU vs. HCFU, r = 0.709), in gastric tissues from 22 patients. The means ± SD of tumor size were -8.5 ± 11.5% for 5-FU, -8.3 ± 16.0% for FT, -18.1 ± 15.8% for UFT and -13.7 ± 13.4% for HCFU. Decrease in tumor size was marked in case of exposure to UFT, compared with that to 5-FU (p &lt; 0.001), FT (p &lt; 0.001) and HCFU (p &lt; 0.05). 18% were sensitive to UFT and resistant to 3 other drugs. Thus, UFT proved to be the most effective among 5-FU and its analogues for decreasing the size of gastric cancer tissues.</jats:p>","journal":"Chemotherapy","year":2009,"id":602803,"datarank":0.44166584687496613,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"self_citation_contribution":0.44166584687496613,"citation_network_contribution":0.0,"self_endowment_contribution":0.44166584687496613,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1546133,"name":"Tetsuya Kusumoto","orcid":null,"position":1,"is_corresponding":false},{"id":1546134,"name":"Hiroko Kusumoto","orcid":null,"position":2,"is_corresponding":false},{"id":1546135,"name":"Hideaki Anai","orcid":null,"position":3,"is_corresponding":false},{"id":1546136,"name":"Keizo Sugimachi","orcid":null,"position":4,"is_corresponding":false},{"id":1433847,"name":"Yoshihiko Maehara","orcid":"0000-0002-1532-3537","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"UFT Is More Antineoplastic against Gastric Carcinoma than 5-Fluorouracil, 1-(2-Tetrahydrofuryl)-5-fluorouracil and 1-Hexylcarbamoyl-5-Fluorouracil","abstract":"<jats:p>The sensitivity of human gastric cancer tissue to 5-fluorouracil (5-FU) and its analogues l-(2-tetrahydrofuryl)-5-fluorouracil (FT), UFT and 1-hexylcarbamoyl-5-fluorouracil (HCFU) was determined, using the in vivo subrenal capsule (SRC) assay. The relative variation of tumor size (ΔTS/TS₀) was calculated as follows: ΔTS/TS₀ = (TS&lt;sub&gt;6&lt;/sub&gt;-TS₀/TS₀) x 100%, where TS&lt;sub&gt;6&lt;/sub&gt; was the tumor size on day 6 and TS₀ on day 0. The chemosensitivity was considered to be positive when ΔTS/TS₀ in the treated group decreased to below -10%. For their cytotoxic effects, 5-FU analogues are converted to 5-FU and positive correlations were noted between the tumor sizes of 5-FU and its analogues (5-FU vs. FT, r = 0.737; 5-FU vs. UFT, r = 0.653; 5-FU vs. HCFU, r = 0.709), in gastric tissues from 22 patients. The means ± SD of tumor size were -8.5 ± 11.5% for 5-FU, -8.3 ± 16.0% for FT, -18.1 ± 15.8% for UFT and -13.7 ± 13.4% for HCFU. Decrease in tumor size was marked in case of exposure to UFT, compared with that to 5-FU (p &lt; 0.001), FT (p &lt; 0.001) and HCFU (p &lt; 0.05). 18% were sensitive to UFT and resistant to 3 other drugs. Thus, UFT proved to be the most effective among 5-FU and its analogues for decreasing the size of gastric cancer tissues.</jats:p>","is_dataset_classified":null,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"3149571","pmcid":null,"openalex_id":"https://openalex.org/W1985820464","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.07722729,"influential_citations":0,"citation_trend":[{"year":2016,"count":1}],"oa_status":"closed","license":"https://karger.com/pages/terms-and-conditions","oa_locations":[{"url":"https://www.karger.com/Article/Pdf/238613","host_type":"publisher"},{"url":"https://karger.com/article-pdf/doi/10.1159/000238613","host_type":"publisher"},{"url":"https://doi.org/10.1159/000238613","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/3149571","host_type":"repository"}],"fields_of_study":["Colorectal Cancer Treatments and Studies","Gastric Cancer Management and Outcomes","Genetic factors in colorectal cancer"],"mesh_terms":["Animals","Antineoplastic Combined Chemotherapy Protocols","Fluorouracil","Tegafur","Male","Stomach Neoplasms","Subrenal Capsule Assay","Uracil","Mice"],"keywords":["Fluorouracil","Gastric carcinoma","Medicine","Oncology","Chemotherapy","Internal medicine","Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T20:21:23.024858Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}